With Incyte’s bread-and-butter Jakafi approaches a 2028 patent cliff, its topical counterpart Opzelura is gaining momentum as several expansion opportunities take shape. More: Incyte's JAK cream Opzelura picks up steam as company works to revive Jakafi XR dreams Source: fierce
read more
New methodology may boost innovation in protein engineering More: Capgemini unveils AI breakthrough to boost bioeconomy Source: News
read more
CSL Behring’s study reveals significant long-term benefits More: Hemgenix shows efficacy among haemophilia B patients Source: News
read moreMerck KGaA is said to be in advanced talks to acquire cancer and are disease specialist SpringWorks, which has a market value of around $3 billion, Reuters reported Monday, citing people close to the matter. Should everything go to plan,
read moreShares of Axsome Therapeutics jumped by more than 20% after the company resolved a patent infringement lawsuit against Teva Pharmaceuticals. The settlement will keep Teva’s generic version of Axsome’s major depressive disorder drug Auvelity off the market until at least
read moreNovartis opened the doors to a €40 million ($41.2 million) viral vector facility in Mengeš, Slovenia, boosting the drugmaker’s investment in the country so far to €3.5 billion ($3.6 billion). The move forms part of Novartis’ greater ambition to expand
read more© 1994 - 2025 B.M. Pharmaceuticals